Patients with small HER2-positive breast cancers (i.e., T1N0 and T2N0 with a tumour size ≤ 3.0 cm) have generally very good prognosis (i.e., DFS > 90% at 7-years) when treated with adjuvant paclitaxel and trastuzumab.34 Here, ERBB2 is linked to breast carcinoma.